Study on the Efficacy and Safety of Tislelizumab Combined with Chemotherapy in Elderly Patients with Lung Cancer
GAO Chenyang
Abstract：Objective:To investigate the efficacy of trastuzumab combined with chemotherapy in elderly patients with lung cancer.Method:A retrospective selection was made of 80 elderly patients(≥65 years old)with first-line lung cancer admitted to Fuqing Hospital from July 2022 to February 2024.According to different treatment plans,the control group(n=40)received chemotherapy,while the observation group(n=40)received additional treatment with trastuzumab.The treatment status was evaluated.Result:The objective response rate(ORR)of the observation group was higher,and the median progression free survival was longer,and the differencese were statistically significant(P<0.05).After treatment,compared with the control group,the above indicators in the observation group were significantly lower,and the differences were statistically signticant(P<0.05).There was no significant difference in adverse reactions between the two groups,and the differencese were statistically significant(P>0.05).Conclusion:Tislelizumab combined with chemotherapy has improved efficacy in the first-line treatment of elderly lung cancer,with no significant increase in adverse reactions and is safe and controllable.
Keywords：TislelizumabChemotherapyElderlyLung cancerEfficacySafety
Publication Date：2025-12-15
Online Publishing Date：2026-01-06(First online date of this platform, not the publication date of the document)
Pages：5( 1-5 )